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Abstract
Oral squamous cell carcinoma is the most common type of cancer in the oral cavity,
representing more than 90% of all oral cancers. The characterization of altered
molecules in oral cancer is essential to understand molecular mechanisms
underlying tumor progression as well as to contribute to cancer biomarker and
therapeutic target discovery. Proteoglycans are key molecular effectors of cell
surface and pericellular microenvironments, performing multiple functions in
cancer. Two of the major basement membrane proteoglycans, agrin and perlecan,
were investigated in this study regarding their role in oral cancer. Using real time
quantitative PCR (qRT-PCR), we showed that agrin and perlecan are highly
expressed in oral squamous cell carcinoma. Interestingly, cell lines originated from
distinct sites showed different expression of agrin and perlecan. Enzymatically
targeting chondroitin sulfate modification by chondroitinase, oral squamous
carcinoma cell line had a reduced ability to adhere to extracellular matrix proteins
and increased sensibility to cisplatin. Additionally, knockdown of agrin and perlecan
promoted a decrease on cell migration and adhesion, and on resistance of cells to
cisplatin. Our study showed, for the first time, a negative regulation on oral cancer-
associated events by either targeting chondroitin sulfate content or agrin and
perlecan levels.
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Introduction
Head and neck cancers are the sixth most common malignancy in the world,
accounting for more than 500,000 new cases every year [1]. Oral squamous cell
carcinoma (OSCC) is the most prevalent cancer occurring in this area [2]. Despite
advancements in prevention and multimodality treatments, oral cancer is still
characterized by poor prognosis and a low survival rate [3–5].
Long-standing as well as recent data implicate tumor extracellular matrix
(ECM) as a significant contributor to tumor progression [6, 7]. However, the
entire process orquestrated by interactions between cancer cells and ECM remains
poorly understood. One of the major constituents of the ECM, the proteoglycans
(PGs), is markedly altered during malignant transformation and tumor
progression. Their role is associated with a number of tumorigenic processes,
including control of cell growth and survival, induction of apoptosis, adhesion,
and invasion [8–10]. Among the main heparan sulfate PGs (HSPG), identified in
basement membrane, are agrin and perlecan, which not only were reported to be
overexpressed in some cancers, such as prostate cancer [11], hepatocellular
carcinoma [12] and breast cancer [13], but also had their function associated with
tumorigenic events [10, 14, 15]. Though, no evidence was reported regarding their
role in oral cancer.
Perlecan is a large proteoglycan (400–500 kDa) harboring five distinct
structural domains, to which long chains of heparan sulfate and/or chondroitin
sulfate are attached [16]. This molecule is present in all vascularized tissues with a
distribution that is primarily confined to basement membranes [17, 18]. Also,
other studies have also identified perlecan in the stromal spaces of various
pathophysiological conditions [19–21].
Agrin shares a rather intriguing multimodular organization with perlecan, but
more complexity to agrin can be added due to at least four sites of alternative
splicing [22]. The amino acid sequence of agrin encodes a protein with a
molecular size of 220 kDa, but the observed molecular weight is around 400 kDa
due to the long heparan sulfate (HS) and chondroitin sulfate (CS) glycosami-
noglycans (GAGs) attached to the core protein [23]. Although originally
discovered in the neuromuscular junctions, agrin has been observed in numerous
other tissues, and it is described as highly expressed in hepatocellular carcinomas
[12, 24, 25] and cholangiocellular carcinomas [12, 24]. Nevertheless, little is
known about its role at locations other than the neuromuscular junctions, and
even less information is known about its role in tumor tissues.
In the present study, we focused on understanding the role of the proteoglycans
agrin and perlecan in oral cancer. First, we sought to validated the overexpression
of agrin and perlecan in oral cancer tissues compared to normal tissues and in cell
lines with different site of origin: oral squamous carcinoma originated from
human tongue (SCC-9), oral squamous carcinoma SCC-9 isolated from lymph
nodes (SCC-9 LN-1) and a skin-derived squamous carcinoma (A431). Next, we
showed that oral squamous carcinoma cell line had a reduced ability to adhere to
extracellular matrix proteins and increased sensibility to cisplatin when treated
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with chondroitinase. By specific target agrin and perlecan protein levels with
siRNA, we showed that OSCC cells have decreased cell adhesion and migration
and increased sensibility to cisplatin treatment. Overall, our findings opened new
avenues to better understand the role of agrin and perlecan, as well as their
involvement in carcinogenesis, which may offer a novel approach to cancer
therapy by targeting the tumor microenvironment.
Materials and Methods
Cell culture
SCC-9 cells (a tumor cell line originated from a human tongue squamous cell
carcinoma) were obtained from the American Type Culture Collection (ATCC,
Manassas, VA) and cultured in DMEM/Ham’s F12 medium (Cultilab),
supplemented with 10% fetal bovine serum (FBS), antibiotics and 0.4 mg/ml
hydrocortisone.
Metastatic oral squamous cell carcinoma (SCC-9) cells were isolated from
lymph nodes (LN-1) originating the cell line SCC-9 LN-1 [26] and cultured as
recommended for SCC-9. Human epidermoid carcinoma, A431, were grown in
Roswell Park Memorial Institute (RPMI)21640 medium supplemented with 10%
FBS and antibiotics. All cell lines were maintained at 37 C˚ in a 5% CO2
atmosphere.
Analysis of mRNA Expression levels
Fresh-frozen OSCC samples (n516) and normal oral mucosa (n516) were used
for perlecan and agrin mRNA levels quantification, using qRT-PCR. All patients
and volunteers enrolled signed a formulary stating their awareness and consent for
the study, approved by the Research Ethics Committee of Faculdade de
Odontologia de Piracicaba, Universidade Estadual de Campinas, UNICAMP,
Piracicaba, Brazil. Clinical pathological data, such as sex, age, anatomical site of
the primary tumor, clinical stage and histopathological grade were collected from
patient’s charts and showed in S1 Table. Brief, total mRNA was isolated from
fresh-frozen tissue samples using mirVana miRNA Isolation Kit (Ambion),
according to the manufacturer’s protocol. First-strand cDNAs were synthesized
from 2mg of DNase-treated total RNA using the SuperScript II Reverse
Transcription Kit (Invitrogen, Carlsbad, CA, USA). Briefly, diluted cDNA product
(1:3) was used to perform a quantitative reverse-transcription polymerase chain
reaction (qRT-PCR) using SYBR Green PCR Master Mix (Applied Bios stems) in
a 7900 Real-Time PCR System (Applied Biosystems, Foster, CA, USA). The
following primers were used to determine mRNA expression levels: Perlecan
forward 59- AAT GCGCTGGACACATTCG-39 and reverse 59-
ATTCACCAGGGCTCGGAAATA-39; Agrin forward
59TTGTCGAGTACCTCAACGCT-39 and reverse 59-
CAGGCTCAGTTCAAAGTCGT-39. PPIA (cyclophilin A) was used as the
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reference gene, forward 59 GCTTTGGGTCCAGGAATGG 39 and reverse 59
GTTGTCCACAGTCAGCAATGGT 39. The PCR cycles were 95 C˚ for 10 minutes,
followed by 40 cycles of 95 C˚ for 15 seconds and 60 C˚ for 1 minute. Each reaction
was performed in triplicate and analyzed individually. The results were calculated
using 22DDCt relative quantification method; relative quantification was normal-
ized to the pooled normal oral tissues, used as reference control.
For analysis of mRNA expression levels in A431, SCC-9 LN-1 and SCC-9 cell
lines, total RNA was obtained using the TRIzol reagent (Invitrogen Corporation)
and 2 mg of total RNA were used for retro-transcription using a First-Strand
cDNA Synthesis Kit (GE Healthcare). Real-time quantitative PCR for agrin and
perlecan was performed using the SYBRH Green PCR Master Mix (Applied
Biosystems), and the dissociation curves were performed to confirm the specificity
of the products. The threshold cycle (CT) values of the targeted gene were
normalized relative to glyceraldehyde-3-phosphate dehydrogenase gene, and
relative expression ratios were calculated using the 22DD Ct method. Two
independent experiments were performed with triplicates.
Immunohistochemistry
High density tissue microarrays were obtained from Biomax (OR601a). The
presence of agrin was analyzed in 10 cancer-adjacent normal tissues and in 47
primary oral squamous cell carcinomas by immunohistochemistry using the
streptavidin-biotin peroxidase complex (Dako). Protein quantification was
assessed with the aid of Aperio Scanscope CS Slide Scanner and the Pixel Count
V9 algorithm software (Aperio Technologies, Vista, CA; USA). By using specific
input parameters, the percentage of cytoplasm positivity was calculated and
classified as weak, moderate and strong, according to its staining intensity. Each
category received an intensity score, 1 to weak, 2 to moderate and 3 to strong
staining. The final score of each tissue sample was calculated as the sum of the
percentage of each category multiplied by their respective intensity scores as the
following formula: Score5(%weak61)+(%moderate62)+(%strong63).
Clinical pathological data, such as sex, age, anatomical site of the primary tumor,
clinical stage and histopathological grade were collected from patient’s charts and
showed in S2 Table.
Chondroitinase treatment
Chondroitinase ABC from Proteus vulgaris (Sigma) was reconstituted in a 0.01%
bovine serum albumin (BSA) aqueous solution to a final concentration of 6 U/ml.
The treatment was performed by diluting the stock chondroitinase in serum free
media to a final concentration of 0.1 U/ml for 4 h at 37 C˚. After treatment, SCC-9
LN-1 cell lines were submitted to adhesion and migration assays.
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In vitro cell migration and adhesion assays
SCC-9, SCC-9 LN-1 or A431 cells, transfected with control siRNA (scramble, sc-
44510, Santa Cruz) or specific siRNA against agrin (sc-29652, Santa Cruz) or
perlecan (sc-44010, Santa Cruz), were submitted either to cell migration or
adhesion assays. Briefly, 36105 cells were plated in 6 well-plate and, after 24 h,
the oligoribonucleotides were transfected with lipofectamine 2000, according to
the manufacturer (Invitrogen).
For the in vitro cell migration assay, cells were harvested after 72 h, plated in
the upper chambers of the transwell (HTS Transwell 96-Well Plate, Corning), and
allowed to migrate towards the lower chamber containing RPMI medium
supplemented with 1% FBS for 16 h. At the end of the assay, the non-migrated
cells at the top chamber were removed using a cotton swab, and the cells at the
bottom of the insert filter were fixed with 10% formaldehyde for 10 min, followed
by PBS washing and then staining with 1% toluidine blue solution in 1% borax,
for 5 min. The dye was eluted using 1% SDS, and the absorbance of stained cells
was measured at 620 nm. Three independent experiments were performed in
triplicates.
SCC-9, SCC-9 LN-1 or A431 siRNAs-transfected cells were also submitted to
cell adhesion assay, as described by Araga˜o et al [27]. After 72 h, cells were seeded
in a 6-well plate (26105) and incubated for 24 h. Then, were washed twice,
incubated in serum-free media for 4 h, and seeded in a Matrigel (2 mg per well;
BD Biosciences) coated 96-well plate, previously three times PBS-washed and
blocked with 3% BSA during 2 h. The adhesion was evaluated during 1 h in
serum-free media supplemented with 3% BSA. The wells were washed 3 times,
and cells fixed with 10% formaldehyde. Cells were then stained with toluidine blue
solution, and absorbance measured at 620 nm, as described above. Three
independent experiments were performed with three replicates.
In vitro viability assay
SCC-9, SCC-9 LN-1 or A431 siRNA-transfected cells (scramble, Agrin or
Perlecan) were seeded onto 96-well plates and incubated at 37 C˚/5%CO2 for two
days. MTT (12 mM tetrazolium 3-(4,5- dimethylthiazol-2)-2,5-diphenyltetrazo-
lium bromide) was added, and cells were kept at 37 C˚ for 4 h, in the dark. The
media was removed, and 100 ml of 1 N HCl/isopropanol (1:25) was added into
each well, followed by gentle agitation at room temperature for 15 min. Finally,
the absorbance was measured at 595 nm. Three independent experiments were
performed in triplicates.
Drug Sensitivity Assay (MTT)
Cisplatin [cis-diammineplatinum(II) dichloride] (Sigma-Aldrich) was dissolved
in 0.150 M NaCl. Aliquots were stored at 220 C˚ for up to a maximum of three
months, and thawed immediately before use.
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Cells (16104) were seeded in 96-well plates and allowed to adhere overnight at
37 C˚. Briefly, following treatments of cells with cisplatin (0; 1; 5; 7.5; 10; 25; 50;
100 mM) for 48 h, MTT reagent [3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenylte-
trazolium bromide] was added to each well, and incubated for 4 h at 37 C˚, in the
dark. The media were removed, 100 ml of 1 N HCl/isopropanol (1:25) was added
in each well, and incubated for 15 min at room temperature under gentle
agitation. Finally, absorbance was measured at 595 nm. Three independent
experiments were performed in triplicates.
Statistical Analysis
Statistical analysis of gene expression validation by qRT-PCR and immunohis-
tochemistry was performed using the non-parametric Kruskal-Wallis followed by
Dunn’s test and Mann-Whitney U test, respectively. For the functional assays
adhesion, migration and proliferation, Student’s t-test or ANOVA followed by
Tukey’s test was used; p-values,0.05 were set as statistically significant. For drug
sensitivity assay, a nonlinear regression curve fit (one phase exponential decay)
was used to analyze cisplatin dose response experiments and determine the IC50.
All the statistical analysis for mRNA expression analysis and functional assays
were performed in GraphPad Prism v6.01.
Results
Agrin and Perlecan are up-regulated in OSCC samples
We started this study by evaluating the mRNA levels of agrin and perlecan, using
qRT-PCR in an independent cohort of OSCC samples and normal oral mucosa.
Higher expression levels of agrin and perlecan were observed in OSCC samples
compared to controls (Fig. 1A, n516, Kruskal-Wallis followed by Dunn’s test,
p,0.05, S1 Table).
We also performed immunohistochemistry analysis in commercial tissue
microarrays containing 10 cancer-adjacent normal tissues and 47 primary OSCCs.
Normal epithelial cells showed weak reactivity for the antibody against agrin, but a
broad positivity was found in the neoplastic cells. Furthermore, there was a
significantly higher expression of agrin in tumor samples, compared to controls
(S1 Figure, Mann-Whitney U test, p,0.0005, S2 Table).
The mRNA levels of agrin and perlecan were evaluated in cell lines with
different sites of origin: oral squamous carcinoma cell line (SCC-9) isolated from
tongue, oral squamous carcinoma cell line (SCC-9) isolated from lymph nodes
(SCC-9 LN-1) and a skin-derived squamous carcinoma (A431). Whereas the
mRNA levels of agrin were higher in SCC-9, the mRNA levels of perlecan were
higher in metastatic SCC-9 LN-1 cell lines. A431 showed an intermediary
expression for both agrin and perlecan (Fig. 1B/C).
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Targeting chondroitin sulfate modification reduced the ability of
SCC-9 LN-1 cells to adhere to extracellular matrix and decreased
the cell resistance to cisplatin
To further understand the general role of chondroitin sulfate post-translational
modification in tumorigenic processes such as cell adhesion and migration, SCC-9
LN-1 cells were treated with 0.1 U/ml of chondroitinase for 4 h in serum free
media, and evaluated for the ability of these cells to adhere to ECM proteins
(Matrigel) and migrate. We showed that SCC-9 LN-1 cells treated with
chondroitinase had lower ability to adhere to ECM proteins compared to the
control (Fig. 2A, n53, Student’s t-test, p,0.05), whereas no significant effect was
observed in the migration of SCC-9 LN-1 cells treated with chondroitinase
(Fig. 2B, n53, Student’s t-test, p.0.05).
Fig. 1. mRNA expression levels of agrin and perlecan. (A) Validation of higher expression of agrin and
perlecan by qRT-PCR in OSCC tumor tissues. Agrin and Perlecan showed higher mRNA expression levels in
human OSCC tumor tissues compared to control tissues by qRT-PCR (Kruskal-Wallis followed by Dunn’s test,
n516, *p,0.05). (B) Agrin showed higher mRNA expression levels in SCC-9 compared to A431 and SCC-9
LN-1 cell lines. (C) Perlecan showed higher mRNA expression levels in SCC-9 LN-1 compared with A431 and
SCC-9 cell lines. The data were normalized with glyceraldehyde-3-phosphate dehydrogenase gene, used as
internal reference). Each bar represents means ¡ SD of at least two independent experiments in triplicates
(one-way ANOVA followed by Tukey’s test. Different letters indicate statistically difference at p,0.05).
doi:10.1371/journal.pone.0115004.g001
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Considering previous studies demonstrated the function of heparan sulfate
modifications in drug uptake [28], we also evaluated the effect of chondroitinase
treatment in the cisplatin cell resistance calculated by the IC50. For that, viability
of the SCC-9, SCC-9 LN-1 and A431 cells were determined in the absence
(vehicle) or presence of 1, 5, 7.5, 10, 25, 50 or 100 mM of cisplatin. The same curve
was constructed with the addition of 0.1 U/ml of chondroitinase. The IC50 of
SCC-9 LN-1, SCC-9 and A431 was 36.31 mM, 21.5 mM and 8.24 mM, respectively.
When chondroitinase was added, SCC-9 LN-1, SCC-9 and A431 cell lines
exhibited a drop in the IC50 (25.62 mM for SCC-9 LN-1, 16.88 mM for SCC-9 and
4.52 mM for A431), decreasing resistance to cisplatin in about 1.5, 1.3 and 1.8 fold
for SCC-9 LN-1, SCC-9 and A431 cells, respectively (Fig. 2C).
Fig. 2. Treatment with chondroitinase ABC decreased SCC-9 LN-1 cell adhesion to extracellular matrix,
but not SCC-9 LN-1 cell migration and increased sensibility of SCC-9 LN-1, SCC-9 and A431 cells to
cisplatin. (A) SCC-9 LN-1 had a lower ability to adhere to extracellular matrix proteins (Matrigel) after
treatment with 0.1 U/ml of chondroitinase for 4 h/37˚C in serum free media (n53, triplicate, Student’s t-test, *
indicates p,0.05). (B) SCC-9 LN-1 was treated with 0.1 U/ml for 4 h/37˚C in serum free media were seeded
in the upper chamber of 96-well transwell plates (n53, triplicate). RPMI media, which was supplemented with
1% FBS, was added in the lower chamber. (C) SCC-9 LN-1, SCC-9 and A431 cells treated with increasing
concentrations of cisplatin (0–100 mM) for 48 h in the presence of 0.1 U/ml of chondroitinase showed
increased sensibility to cisplatin, calculated by a non-linear regression of a dose-response curves (log[mM
cisplatin] vs normalized response). Data are expressed as means ¡ SD from one independent experiment.
doi:10.1371/journal.pone.0115004.g002
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Expression-associated phenotype of agrin and perlecan in
adhesion, migration and proliferation event
In order to investigate the role of agrin and perlecan in oral carcinogenesis, we
first evaluated the ability of the cells to adhere to extracellular matrix proteins.
First, SCC-9, SCC-9 LN-1 and A431 cells lines were scramble-siRNA, agrin-siRNA
or perlecan-siRNA transfected, and knockdown of agrin and perlecan were
confirmed by qRT-PCR (S2 Figure). We observed that targeted agrin knockdown
decreased the adhesion of SCC-9 and SCC-9 LN-1 cells to the Matrigel (Fig. 3A
and B, n53, Student’s t-test, p,0.05), but no significant effect was observed for
agrin knockdown in A431 cells. The knockdown of perlecan decreased the
adhesion of SCC-9 LN-1 and A431 cells (Fig. 3C and D, n53, Student’s t-test,
p,0.05), but no significant effect was observed for perlecan knockdown in SCC-9
cells.
The role of agrin and perlecan in cell migration was determined using transwell
chamber. First, SCC-9, SCC-9 LN-1 and A431 cells treated with control siRNA
(scramble) and siRNA against agrin or perlecan were plated in the upper
chambers, and allowed to migrate towards the lower chamber containing medium
supplemented with 1% FBS. For agrin silenced cells, migration was significantly
diminished in SCC-9, SCC-9 LN-1 and A431 cells compared to scrambled control
(Fig. 4A–D, n53, Student’s t-test, p,0.001). For perlecan silenced cells,
migration was significantly diminished in SCC-9 LN-1 and A431 cells compared
to scrambled control.
Cell viability was tested using MTT assay in the presence of 10% FBS, and we
verified that SCC-9 and SCC-9 LN-1-agrin knockdown had a significant
reduction in cell viability (Fig. 5A, n53, One-way ANOVA, followed by Tukey’s
test, p,0.001). In the A431 knockdown cells no significant difference was
observed for agrin- or perlecan-siRNA, compared to the scrambled-siRNA
(Fig. 5B).
The role of agrin and perlecan in cisplatin cell resistance
We sought to determine the cisplatin cell resistance in SCC-9, SCC-9 LN-1 and
A431 when agrin or perlecan was silenced in these cell lines. It was observed that
the siRNA-knockdown of agrin promoted a reduction in the cisplatin cell
resistance in all cell lines used in this study: SCC-9 (2.4 fold), SCC-9 LN-1 (3.8
fold) and A431 (1.7 fold) (S3 Figure). On the other hand, when perlecan was
silenced, no significant difference was observed in cisplatin cell resistance for SCC-
9, SCC-9 LN-1 and A431 cell lines compared with scrambled (S3 Figure).
At a concentration of 10 mM of cisplatin, SCC-9, SCC-9 LN-1 and A431 cell
lines showed a significant reduction in cell viability when agrin expression was
silenced (Fig. 6A and B, n53, ANOVA followed by Tukey’s test, p,0.05). A
significant reduction in cell viability was also observed just in A431 perlecan-
knockdown cells treated with 10 mM of cisplatin (Fig. 6C, n53, ANOVA followed
by Tukey’s test, p,0.05).
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Discussion
Proteoglycans (PGs), essential macromolecules of the tumor microenvironment,
have their expression altered during malignant transformation and tumor
Fig. 3. The role of agrin and perlecan in cell adhesion. Knockdown of agrin decreased adhesion to Matrigel
in SCC-9 (n52, A) and SCC-9 LN-1 (n53, B), while no difference was observed in A431 (n53, C). When
perlecan was silenced by siRNA no difference was observed in SCC-9 adhesion to Matrigel (n52, D) but a
significant reduction was observed in SCC-9 LN-1 (n53, E) and A431 (n53, F) adhesion to Matrigel
(Student’s t-test, * indicates p,0.05).
doi:10.1371/journal.pone.0115004.g003
Fig. 4. The role of agrin and perlecan in cell migration. Knockdown of agrin decreased migration of SCC-9
(n52, A), SCC-9 LN-1 (n53, B) and A431 (n53, C) cell lines. When perlecan was silenced by siRNA no
difference was observed in SCC-9 migration (n52, D), but a significant reduction was observed in SCC-9 LN-
1 (n53, E) and A431 (n53, F) migration (Student’s t-test, * indicates p,0.05).
doi:10.1371/journal.pone.0115004.g004
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progression [9]. Agrin and perlecan are two of the major HSPG identified in the
basement membrane, and their functional roles in modulation of cancer growth
have been reviewed elsewhere [22]. In this study, we showed for the first time that
agrin and perlecan are highly expressed in OSCCs, and the function of these
proteins in oral cancer associated processes was investigated. Not only the
expression of agrin and perlecan was shown to be higher in OSCC tissues
compared to control tissues, but also their expression might be associated with
different sites of origin, where higher expression of agrin was found in cell line
originated from primary site (SCC-9), whereas higher expression of perlecan was
found in cell line originated from metastatic site (SCC-9 LN-1). The spread of
cancer cells from a primary tumor to form metastases at distant sites is a complex
process that remains poorly defined [29], but it has been reported to involve
detachment of cells from the tumor tissue, regulation of cell motility and invasion,
proliferation and evasion through the lymphatic system or blood vessels [30].
Efforts have been made to elucidate tumor-related proteins that could influence
the appearance of metastases in oral squamous cell carcinoma [31–33], which
Fig. 5. The role of agrin and perlecan in cell viability. The viability of SCC-9 (n52, A) and SCC-9 LN-1
(n53, B) was significantly reduced after siRNA-knockdown of agrin, but no difference in viability was observed
in perlecan knockdown. The viability of A431 was not altered neither by agrin knockdown nor by perlecan
knockdown (n53, C) (One-way ANOVA followed by Tukey’s test, different letters indicate statistically
difference at p,0.05).
doi:10.1371/journal.pone.0115004.g005
Fig. 6. Viability of SCC-9 LN-1 and A431 cell lines in 10 mM of cisplatin treatment. At 10 mM of cisplatin,
the viability of SCC-9 (n53, A), SCC-9 LN-1 (n53, B) and A431 (n53C) was significantly reduced when agrin
was silenced. Only in A431 cell line the same result of decreasing in viability was observed for perlecan
siRNA-knockdown (C) (One-way ANOVA followed by Tukey’s test, different letters indicate statistically
difference at p,0.05).
doi:10.1371/journal.pone.0115004.g006
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occur in about 40% of patients with oral cancer [34]. Therefore, the study of
altered molecules in cell lines originated from distinct sites is essential to
understand the molecular basis of this process.
GAGs polysaccharide chains are the main contributors to the proteoglycan
functional properties and essential part of the matured proteoglycan molecules
[35]. Besides, it was reported that glycans play a crucial role at various
pathophysiological steps of cancer progression [36], especially by acting as co-
receptors to stabilize growth-factor receptor signaling complexes and enhancing
integrin-mediated cell adhesion, motility and intracellular signaling. The
disruption of GAGs modification by heparanase was shown to facilitate tumor cell
invasion [37] angiogenesis and metastasis [38]. In order to further understand the
role of chondroitin sulfate modification in oral cancer, SCC-9 LN-1 cell lines were
treated with chondroitinase and tested in adhesion and migration processes.
Interestingly, when SCC-9 LN-1 cells were treated with chondroitinase, they had
reduced ability to adhere to extracellular matrix proteins. It is important to
mention that this event may be a result of the disruption of many cell surface
chondroitin sulfate proteoglycans, such as syndecans, chondroitin sulfate
proteoglycan 4, betaglycan, neuropilin-1, receptor protein tyrosine phosphatase,
integrin and VEGFR-2, which were also previously demonstrated to be
overexpressed in cancer [39].
It is well established that based upon their direct involvement in cell–cell and
cell–ECM interactions, PGs have been strongly implicated in the regulation of cell
movement [40]. However, how PGs actually affect this process is only partially
understood and in some instances, controversial. In this study, we have
demonstrated that agrin and perlecan play a role in the oral cancer cell movement
by silencing agrin and perlecan, which promoted a strongly reduced in the ability
of SCC-9 and SCC-9 LN-1 cell line to migrate and to adhere to matrigel.
Perlecan has been associated with the induction of cellular proliferation,
differentiation and angiogenesis by interacting with a number of growth factors
including FGFs 1, 2, 7, 9, and 18; hepatocyte growth factor, platelet derived
growth factors-AA and -BB, and VEGF [14, 41]. Perlecan also exhibits adhesive
[42] or anti-adhesive [43] properties presumably by differentially affecting surface
receptors such as a2b1 integrin [44, 45]. Agrin is also able to interact with
integrins [46], however there is still very limited acknowledgement on how agrin
signals through the integrin receptors and how these interactions influence cell
behavior.
Therapeutic PGs- and GAG-targeting modifications have been considered as
anti-invasion and tumor-specific drug delivery potential approaches [47]. It was
reported that both heparan sulfate and chondroitin sulfate modifications are able
to interact with cisplatin and mediate entry-pathway [28, 48]. Platinum-based
chemotherapy has been used for treating a wide variety of solid tumors, including
lung, head and neck, ovarian, cervical, and testicular cancers for over three
decades [49]. However, the emergence of drug resistance may limit the
effectiveness of platinating agents in solid tumors [50–52], including OSCCs [53].
Recently, novel extracellular matrix cisplatin-resistant biomarkers from epithelial
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ovarian carcinoma (EOC) were identified using secretome analysis from EOC cell
lines [54]. In our study, we showed new evidences of increasing cisplatin-
sensibility by disrupting chondroitin sulfate modification, or reduction of agrin
and perlecan proteins levels, suggesting it may have a potential target for
therapeutic intervention.
In summary, we have identified a relevant role of agrin and perlecan in oral
cancer cell adhesion, migration and cisplatin cell resistance, opening new
perspectives for further investigations and targeting innovative and/or comple-
mentary therapeutic strategies.
Supporting Information
S1 Figure. Immunohistochemistry analysis of agrin in tissue microarray. Agrin
showed higher expression in OSCC (n547) compared with normal mucosa
(n510) (Mann-Whitney U test, p,0.0005). In lower panel, two representative
figures show the higher expression of agrin in OSCC (B) compared with normal
mucosa (A).
doi:10.1371/journal.pone.0115004.s001 (TIF)
S2 Figure. Confirmation by qRT-PCR of silencing of agrin in SCC-9 (A), SCC-9
LN-1 (B) and A431 (C) and perlecan in SCC-9 (D), SCC-9 LN-1 (E) and A431
(F). The data were normalized with the (glyceraldehyde-3-phosphate dehydro-
genase gene was used as internal reference). Each bar represents mean¡ SD of at
least two independent experiments in triplicates.
doi:10.1371/journal.pone.0115004.s002 (TIF)
S3 Figure. The role of agrin and perlecan in cisplatin cell resistance. (A) SCC-9/
control (scrambled, IC50514.57 mM), SCC-9/siRNA Agrin (IC5056.02 mM) and
SCC-9/siRNA Perlecan (IC50512.68 mM) were treated with increasing concen-
trations of cisplatin (0–100 mM) for 48 h and the IC50 concentrations were
calculated using dose response curves generated by GraphPad Prism software. (B)
SCC-9 LN-1/control (scrambled, IC50517.65 mM), SCC-9 LN-1/siRNA Agrin
(IC5054.662 mM) and SCC-9 LN-1/siRNA Perlecan (IC50515.55 mM) were
treated with increasing concentrations of cisplatin (0–100 mM) for 48 h and the
IC50 concentrations were calculated using dose response curves generated by
GraphPad Prism software. (C) A431/control (scrambled, IC5056.59 mM), A431/
siRNA Agrin (IC5053.85 mM) andA431/siRNA Perlecan (IC5056.65 mM) were
treated with increasing concentrations of cisplatin (0–100 mM) for 48 h and the
IC50 concentrations were calculated using dose-response curves generated by
GraphPad Prism software.
doi:10.1371/journal.pone.0115004.s003 (TIF)
S1 Table. Clinicopathological characteristics of the patients with OSCC in the
TMA.
doi:10.1371/journal.pone.0115004.s004 (XLSX)
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S2 Table. Clinicopathological characteristics of the patients with OSCC used in
the qRT-PCR analysis.
doi:10.1371/journal.pone.0115004.s005 (XLSX)
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